SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,735.00+0.07%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%
Benzinga

Health Care

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
What's Going on With Ginkgo Bioworks Stock on Friday?
What's Going on With Ginkgo Bioworks Stock on Friday?
CVS Health's Aetna Says Strong Medicare Star Ratings Boost Confidence in Return to Appropriate Margins
CVS Health's Aetna Says Strong Medicare Star Ratings Boost Confidence in Return to Appropriate Margins

Health Care Recent News

XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.
UK Revokes Approval for Valneva's Chikungunya Shot
UK Revokes Approval for Valneva's Chikungunya Shot
UK MHRA revokes Valneva’s IXCHIQ chikungunya vaccine authorization over traveler benefit-risk review. Minimal financial impact expected.
AngioDynamics Stock Is Falling Thursday: What's Going On?
AngioDynamics Stock Is Falling Thursday: What's Going On?
ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.
Why Is Neogen Stock Gaining Thursday?
Why Is Neogen Stock Gaining Thursday?
Neogen (NEOG) stock rises after outlining ambitious FY31 targets at Investor Day, including 30% EBITDA margins & R&D expansion.
Tilray Brands Not Dependent on Single Market, CEO Highlights Multiple Growth Engines
Tilray Brands Not Dependent on Single Market, CEO Highlights Multiple Growth Engines
Tilray Brands Q1 adjusted EPS beats consensus despite revenue shortfall. BrewDog acquisition fuels an 82% surge in beverage revenue.
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx announced Phase 2 success for FB102 in celiac disease while halting its Phase 3 UNITY study in Sjögren's disease for futility.
Why is AbbVie (ABBV) Stock Trending After Hours?
Why is AbbVie (ABBV) Stock Trending After Hours?
AbbVie Inc. Shares rose 0.44% after hours following FDA breakthrough designations for telisotuzumab adizutecan in two cancers.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved